736994-05-1

Basic information

• Product Name: 7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4(3H)-one
• Synonyms: 7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4(3H)-one
• CAS NO: 736994-05-1
• Molecular Weight: 371.225
• Mol File: 736994-05-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4(3H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4(3H)-one(736994-05-1)
• EPA Substance Registry System: 7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4(3H)-one(736994-05-1)

Safety Data

• Hazardous Substances Data: 736994-05-1(Hazardous Substances Data)

Upstream product

• 530-62-1 1,1'-carbonyldiimidazole 
• 622-95-7 4-chlorobenzyl bromide 
• 609-65-4 o-chlorobenzoyl chloride 
• 7504-29-2 1-(2-chlorophenyl)-2-(4-chlorophenyl)ethanone 
• 1153577-11-7 C₁₈H₁₅Cl₂N₃ 
• 916728-81-9 2-bromo-1-(2-chlorophenyl)-2-(4-chlorophenyl)-ethanone 
• 736994-02-8 7-(2-chlorophenyl)-8-iodo-2-methylpyrazolo[1,5-a][1,3,5]triazin-4(3H)-one 
• 1679-18-1 4-Chlorophenylboronic acid 
• 1153577-09-3 N-(3-(2-chlorophenyl)-4-(4-chlorophenyl)-1H-pyrazol-5-yl)acetamidine 

Downstream Products

• 736994-06-2 4-chloro-7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazine 

Relevant articles and documents

Development of two synthetic routes to CE-178,253, a CB1 antagonist for the treatment of obesity

CE-178,253 benzenesulfonate (1) is a CB1 antagonist discovered by Pfizer medicinal chemists. Two syntheses of this compound are described. The first, based on the discovery synthesis, involves assembly of an aryl-substituted pyrazolotriazine core onto which the second aryl moiety is installed by a Suzuki coupling; this route has been scaled to provide up to 6 kg of API. A second, more convergent route is also described, which installs the pyrazolotriazine containing both aryl substituents by condensation of a bromoketone with a substituted thiosemicarbazide. This route has been demonstrated on laboratory scale and is viewed as the preferred bond-forming sequence.

PYRAZOLO`1,5-A!`1,3,5! TRIAZIN -4-ONE DERIVATIVES AS CB1 RECEPTOR ANTAGONISTS

Compounds of Formula (I) are described herein. The compounds have been shown to act as cannabinoid receptor ligands and are therefore useful in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals.